Bristol-Myers beats forecasts, as hepatitis, cancer drugs deliver

July 28 (Reuters) - Bristol-Myers Squibb Co reported better than expected quarterly results, fueled by sales of its treatments for hepatitis C, cancer and blood clots, and slightly raised its full year profit forecast.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.